정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1409 | Not yet recruiting | Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial | Covid19 | Biological: Triple dose vaccination by inactivated Covid19 vaccine | Phase 2 | Health Institutes of Turkey, TC Erciyes University, Kocak Farma, Mene Research | OTHER_GOV | 200 | All | 18 Years ~ 64 Years | Erciyes University Hakan Cetinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP), Kayseri, Turkey |
| 1408 | Active, not recruiting | Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 | To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care | Drug: Ivermectin | Phase 3 | Raincy Montfermeil Hospital Group | NETWORK | 200 | All | 18 Years | GHI Le Raincy Montfermeil, Montfermeil, France |
| 1407 | Terminated | Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients | Sars-CoV2 | Drug: Hydroxychloroquine (HCQ) | Phase 3 | Centre Hospitalier Universitaire de Saint Etienne, CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang | OTHER | 7 | All | 18 Years | Groupement Hospitalier des Portes de Province, Montelimar, France Centre Hospitalier de Roanne, Roanne, France CHU Saint-Etienne, Saint-Etienne, France Clinique Mutualiste, Saint-Etienne, France |
| 1406 | Active, not recruiting | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | COVID-19 | Biological: SARS-CoV-2 rS - Phase 1 Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 Other: Normal saline solution (NSS), Placebo - Phase 1 Other: Normal saline solution (NSS), Placebo - Phase 2 Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1 Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 |
Phase 2 | Novavax, Coalition for Epidemic Preparedness Innovations | INDUSTRY | 1419 | All | 18 Years ~ 84 Years | Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2, Savannah, Georgia, United States Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2, Meridian, Idaho, United States Alliance for Multispecialty Research, LLC - Phase 2, Newton, Kansas, United States Alliance for Multispecialty Research, LLC - Phase 2, Wichita, Kansas, United States Central Kentucky Research Associates Inc - Phase 2, Lexington, Kentucky, United States Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2, Rockville, Maryland, United States Synexus Clinical Research US, Inc. - Cincinnati - Phase 2, Cincinnati, Ohio, United States Rapid Medical Research Inc - ERN-PPDS - Phase 2, Cleveland, Ohio, United States Paratus Clinical Research - Canberra - Phase 2, Bruce, Australian Capital Territory, Australia Paratus Clinical Research - Western Sydney - Phase 2, Blacktown, New South Wales, Australia Paratus Clinical Research - Central Coast - Phase 2, Kanwal, New South Wales, Australia Australian Clinical Research Network - Phase 2, Maroubra, New South Wales, Australia Scientia Clinical Research Limited - Phase 2, Randwick, New South Wales, Australia Q Pharm Pty Limited - Phase 1, Herston, Queensland, Australia University of the Sunshine Coast, Health Hub Morayfield - Phase 2, Morayfield, Queensland, Australia University of the Sunshine Coast - Phase 2, Sippy Downs, Queensland, Australia Barwon Health - Phase 2, Geelong, Victoria, Australia Center for Clinical Studies - Phase 1 and Phase 2, Melbourne, Victoria, Australia |
| 1405 | Active, not recruiting | Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine | Covid19 | Biological: ICC Vaccine Biological: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant Biological: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant |
Phase 2 | Novavax | INDUSTRY | 642 | All | 50 Years ~ 70 Years | Paratus Clinical Research - Canberra, Bruce, Australian Capital Territory, Australia Paratus Clinical Research - Western Sydney, Blacktown, New South Wales, Australia Northern Beaches Clinical Research, Brookvale, New South Wales, Australia Paratus Clinical Research - Central Coast, Kanwal, New South Wales, Australia Hunter Diabetes Centre, Merewether, New South Wales, Australia University of the Sunshine Coast,Southbank, Brisbane, Queensland, Australia University of the Sunshine Coast, Health Hub Morayfield, Morayfield, Queensland, Australia University of the Sunshine Coast, Sippy Downs, Queensland, Australia Austrials Pty Ltd - Taringa, Taringa, Queensland, Australia Emeritus Research, Camberwell, Victoria, Australia |
| 1404 | Not yet recruiting | Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults | Covid19 | Biological: SII B.1.351 Biological: SII B.1.351 Biological: SII Bivalent Biological: SII Bivalent Biological: SII B.1.617.2 |
Phase 2 | Novavax | INDUSTRY | 240 | All | 18 Years ~ 64 Years | Paratus Clinical Research - Western Sydney, Blacktown, New South Wales, Australia Paratus Clinical Research - Central Coast, Kanwal, New South Wales, Australia Australian Clinical Research Network (ACRN), Maroubra, New South Wales, Australia Holdsworth House Medical Practice - Sydney, Sydney, New South Wales, Australia University Hospital Geelong-Barwon Health, Geelong, Victoria, Australia Emeritus Research, Melbourne, Victoria, Australia |
| 1403 | Recruiting | Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection | SARS-CoV-2 | Drug: EXO-CD24 | Phase 1 | Tel-Aviv Sourasky Medical Center | OTHER_GOV | 35 | All | 18 Years ~ 85 Years | Tel Aviv Medical Center, Tel Aviv, Israel |
